Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
aTHermaVac - a Therapeutic Herpes Simplex Type 2 mRNA Vaccine
| Reference number | 2023-03942 |
| Coordinator | Eurocine Vaccines AB |
| Funding from Vinnova | SEK 0 |
| Project duration | May 2024 - April 2026 |
| Status | Completed |
| Venture | Swelife - Collaboration project for better health |
| Call | Swelife - Collaborative projects for better health autumn 2023 |
Last updated 3 June 2024
Reference number 2023-03942
